Description
The Multiple Myeloma Minimal Residual Disease Panel (MM-MRD) is comprised of a pre-mixed 6-color 8-antibody combination and two single antibody vials : CD138-BV421 and CD27-BV510. The panel is designed for the qualitative and semi-quantitative identification and discrimination of malignant and normal plasma cells by flow cytometry using BD FACSCanto™ II and/or BD FACSLyric™ Flow Cytometers. It is intended to be used for staining of bone marrow specimens of Multiple Myeloma treated patients.
The Multiple Myeloma Minimal Residual Disease Panel recignizes the following antigens: CD138, CD27, CD38, CD45, CD56, CD19, CD81, CD117, cytoplasmic IgKappa and IgLambda.
| Description | Quantity/Size | Part Number | EntrezGene ID |
|---|---|---|---|
| MM-MRD8 Tube 1 | 5 Tests (4 ea) | CYT-MM-MRD8-T1-V | N/A |
| MM-MRD8 Tube 2 Surface | 5 Tests (4 ea) | CYT-MM-MRD8-T2S-V | N/A |
| MM-MRD8 Tube 2 Cytoplasmic | 5 Tests (4 ea) | CYT-MM-MRD8-T2CY-V | N/A |
| CD19-PE-Cyanine7 Compensation | 1 Test (1 ea) | CYT-MM-MRD8-CD19COMP | N/A |
| CD45-PerCP-Cyanine5.5 Compensation | 1 Test (1 ea) | CYT-MM-MRD8-CD45COMP | N/A |
| CD81-APC-C750 Compensation | 1 Test (1 ea) | CYT-MM-MRD8-CD81COMP | 975 |
| Lambda-APC-C750 Compensation | 1 Test (1 ea) | CYT-MM-MRD8-LAMBCOMP | N/A |
| Fix&Perm® Solution A | 20 Tests (1 ea) | CYT-MM-MRD8-F&P-SOLA | N/A |
| Fix&Perm® Solution B | 20 Tests (1 ea) | CYT-MM-MRD8-F&P-SOLB | N/A |
| CD138-BV421 | 50 Tests (1 ea) | CYT-MM-MRD8-138 | 6382 |
| CD27-BV510 | 50 Tests (1 ea) | CYT-MM-MRD8-27 | 939 |
| Bulklysis | 20 Tests (1 ea) | CYT-MM-MRD8-BL | N/A |
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For In Vitro Diagnostics Use.
Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.